Healthcare
Proteonomix, Inc.(PROT)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
- Market Cap
- —
- Revenue Growth
- -68.8%
- EPS Growth
- +72.0%
- Dividend Yield
- 0.0%
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Proteonomix, Inc. (PROT) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of -68.8%, EPS growth of +72.0%, a dividend yield of 0.0%. What stands out right now is revenue -68.8%, EPS +72.0%, free cash flow +59.6% with operating margin -5026.1% and ROIC 604.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PROT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-68.8% vs +7.6% peer median
Operating Margin
Below sector median
-5026.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -68.8% and EPS is at +72.0%, with operating margin around -5026.1%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PROT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PROT Max Drawdown
-99.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PROT and SPY.
Company Overview
Proteonomix, Inc.
Other OTC
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
- Leadership
- Michael Cohen
- IPO Date
- Jul 31, 1997
- Employees
- 2
- Street Address
- 145 Highview Terrace
- Mailing
- Hawthorne, NJ, 07506
- Region
- Hawthorne, NJ, US
- Reporting Currency
- USD
- Investor Line
- 973-949-4193
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 0.0
- Price/Book
- —
Growth
- Revenue
- -68.8%
- EPS
- +72.0%
- Free Cash Flow
- +59.6%
Profitability
- Gross Margin
- 102.0%
- Operating Margin
- -5026.1%
- Net Margin
- -5322.3%
- ROE
- 38.8%
- ROIC
- 604.7%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.